News | November 09, 2023
Biocon Biologics announces divestment of two non-core branded formulations
Total transaction value of the divestment is Rs. 3,660 million
Total transaction value of the divestment is Rs. 3,660 million
Bains has stepped down from his role on the Biocon Board as an Independent Director with immediate effect
The return profile of NCDs is linked to BBL share price subject to minimum IRR of 12%.
Biocon Biologics Limited will have access to 100 million doses of vaccines annually together with the distribution rights to Serum's Vaccine portfolio
The proposed transaction involves the sale of the global biosimilars portfolio of Viatris to Biocon Biologics
BRIDGE-1 Comprehensive care programme for Type 1 diabetes and to train 400 physicians and benefit over 1000 children
Subscribe To Our Newsletter & Stay Updated
